Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes
Authors:
- 1 October 2004
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (10) , 2363-2368
Abstract
OBJECTIVE—Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin. RESEARCH DESIGN AND METHODS—In total, 876 relatively well-controlled patients with type 2 diabetes (mean HbA1c 7.55%) were randomized and treated with glulisine/NPH (n = 435) or RHI/NPH (n = 441) for up to 26 weeks in this randomized, multicenter, multinational, open-label, parallel-group study. Subjects were allowed to continue the same dose of prestudy regimens of oral antidiabetic agent (OAD) therapy (unless hypoglycemia necessitated a dose change). RESULTS—A slightly greater reduction from baseline to end point of HbA1c was seen in the glulisine group versus RHI (−0.46 vs. −0.30% with RHI; P = 0.0029). Also, at end point, lower postbreakfast (156 vs. 162 mg/dl [8.66 vs. 9.02 mmol/l]; P < 0.05) and postdinner (154 vs. 163 mg/dl [8.54 vs. 9.05 mmol/l]; P < 0.05) blood glucose levels were noted. Symptomatic hypoglycemia (overall, nocturnal, and severe) and weight gain were comparable between the two treatment groups. There were no between-group differences in baseline-to-end point changes in insulin dose. CONCLUSIONS—Twice-daily glulisine associated with NPH can provide small improvements in glycemic control compared with RHI in patients with type 2 diabetes who are already relatively well controlled on insulin alone or insulin plus OADs. The clinical relevance of such a difference remains to be established.Keywords
This publication has 13 references indexed in Scilit:
- The Treat-to-Target TrialDiabetes Care, 2003
- Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic PatientsDiabetes Care, 2003
- Glucose Tolerance and Cardiovascular MortalityArchives of internal medicine (1960), 2001
- A desktop guide to Type 2 diabetes mellitusDiabetic Medicine, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care, 1997
- Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study GroupArchives of internal medicine (1960), 1997
- Mealtime Treatment With Insulin Analog Improves Postprandial Hyperglycemia and Hypoglycemia in Patients With Non-Insulin-Dependent Diabetes MellitusArchives of internal medicine (1960), 1997
- Role of insulin resistance in the pathogenesis of NIDDMDiabetologia, 1995
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28AspDiabetic Medicine, 1993